Synovial sarcoma is a very rare malignant neoplasm. There is a whole group of causes of pain and inflammation in your joints. One of them is the presence of cancerous tumors. Maziak is a primary tumor that occurs in people of all ages, but is more common in younger people during the growth period. It accounts for 7-10 percent of all soft tissue sarcomas.

Synovial sarcoma(malignant synovial sarcoma, SS, sarcoma synoviale) iscancermalignant, belonging to the group of soft tissue sarcomas, originating from the capsule synovial joint, tendon sheaths, bursae and synovial appendages. In 80 percent. develops in the limb location in the vicinity of large joints.

Mazovian maziak is 5-10 percent. all sarcomas. It most often occurs before the age of 50, usually between the ages of 25-35.

Synovial sarcoma -How to recognize the symptoms

In the case of limb localization, synovial sarcoma is:

  • strong, increasing pain in the lower limb
  • disturbed gait
Important

Sarcomas of meat tissues in Poland account for about 7 percent. all childhood malignancies. Most cases occur in children aged 2-6 and adolescents over 12 years of age. The most common cancer in this group in children is rhabdomyosarcoma (RMS) - 69.0%. and synovial sarcoma - 10.2 percent. The 5-year survival rate since the diagnosis of the disease is 60 percent.

Synovial sarcoma - treatment

Surgery is the primary treatment method, usually in combination with adjuvant radiotherapy (as in other higher-grade sarcomas). It is a type of soft tissue sarcoma with relatively good sensitivity to chemotherapy (especially ifosfamide in high doses).

Synovial sarcoma - prognosis

Low survival rates (10 years between 30-50%) have changed recently due to the introduction of the principles of treatment combined with radiotherapy and perioperative chemotherapy.

Synovial sarcoma - metastases

Metastases of synovial sarcoma in most cases occur to the lungs, but relatively more frequent compared to other types of sarcomas are metastases to regional lymph nodes (5-20%) and bones (approx. 10%).

Category:

Oncology